Highlight
- A single booster dose of GBS6 approximately two years after primary vaccination is well-tolerated and safe in healthy, non-pregnant adults.
- Booster immunisation elicits robust serotype-specific IgG antibody responses, significantly exceeding those observed after the primary dose.
- Antibody levels wane over two years post-primary immunisation but remain elevated above baseline, supporting durability of response.
- Findings provide a foundation for potential booster strategies in maternal immunisation aiming to protect infants from invasive GBS disease.
Study Background
